The present invention relates to a novel ethynylxanthine derivatives of formula (I) which exhibit ability selectively suppress matrix metalloproteinases and therefore may act as inhibitors of angiogenesis, methods for their synthesis and use for the treatment and/or prevention of various diseases and disorders caused by overexpression of matrix metalloproteinases by administration of such substances.